Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annu... ( Phase 3 Safety and Efficacy Studi...)

HOME >> MEDICINE >> NEWS

Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting

Date:5/7/2008

Phase 3 Safety and Efficacy Studies Will Be Highlighted

TAMPA, Fla., May 7 /PRNewswire-USNewswire/ -- Acute pain is a significant medical issue in the United States. More than 25 million Americans are said to experience acute pain each year as a result of injuries or surgeries, and a recent study estimated that 42 percent of U.S. hospital emergency department visits were due to pain-related problems.

Seven clinical presentations on tapentadol immediate release (IR) tablets for acute pain, including pivotal Phase 3 safety and efficacy and gastrointestinal tolerability data, will be discussed during the poster sessions of the 27th Annual Scientific Meeting of the American Pain Society (APS) in Tampa, Florida on Thursday, May 8 and Friday, May 9.

These data presentations are supported by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD).

Tapentadol is a novel investigational, centrally acting oral analgesic. It has a unique profile with two mechanisms of action, combining mu-opioid receptor agonism and norepinephrine reuptake inhibition in a single molecule. It is being developed in immediate-release formulation for acute pain and extended-release formulation for chronic pain.

Mu-opioid agonists are drugs that bind to and activate mu-opioid receptors in the central nervous system. These drugs modify sensory and affective (mood) aspects of pain, inhibit the transmission of pain at the spinal cord and affect activity at parts of the brain that control how pain is perceived. Norepinephrine reuptake inhibitors are a type of central nervous system medication that increases the level of norepinephrine in the brain by inhibiting its re-absorption into nerve cells; these compounds have analgesic properties.

The following tapentadol immediate release studies will be presented at APS:

Thursday, May 8: 4:45 p.m. to 6:15 p.m.

Poster 223: Evidence for a Combined Mode of Action Unde
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Health Level Seven Appoints John Quinn as CTO
2. AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States
3. Kaiser Permanente Study Shows One in Seven Women are Depressed Before, During, or After Pregnancy
4. Hospital Corporation of America Purchases Seventh CyberKnife(R) System
5. Seven Finalists Announced for 2007 Insight Award for Customer Advocacy in Healthcare
6. New Poll Finds Nearly Seven in 10 New Jersey Voters Support Smoke-Free Casinos
7. President Musevenis Visit Protested by HIV/AIDS Experts
8. HealthPartners is National Benchmark in Six Out of Seven Areas in National Business Coalition on Health Report
9. CNN Honors Extraordinary Deeds of Seven Everyday People in Global Event
10. Medifast, Inc. Receives Approval to Sell Medifast Weight Control Centers Franchises in Seven Additional States
11. Seven Community Service Organizations Granted Over $60,000 From Delta Dental Of Illinois

Post Your Comments:

Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annu...( Phase 3 Safety and Efficacy Studi...),Health